Form 8-K · Current Report · Filed 2025-07-31
Alnylam Pharmaceuticals Reports Strong Q2 2025 Financial Results and Raises Guidance
Alnylam Pharmaceuticals, Inc. reported its financial results for the second quarter of 2025, showing a 64% year-over-year increase in total net product revenues to $672 million, driven primarily by strong performance from its AMVUTTRA product. The company also raised its 2025 guidance for TTR franchise net revenues to a range of $2,175 million to $2,275 million and total net product revenues to a range of $2,650 million to $2,800 million, representing a 27% increase at the midpoint. These results reflect the successful commercial launch of AMVUTTRA and the growing demand for innovative RNAi therapeutics.
- Filer
- Alnylam Pharmaceuticals Inc. ALNY · NASDAQ
- Filed
- Accession
- 0001178670-25-000089
- CIK
- 0001178670
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$339.80
Next session
+18.2%
Since filing
-39.5%
Latest close
$205.52
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ALNY reporting the same item, with the next session's move:
Exhibits (1)
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Never miss another ALNY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.